Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 6, 2003, Pages 775-783

  Williams, M P ^a   Usselmann, B ^b   Chilton, A ^b   Sercombe, J ^a   Nwokolo, C U ^b   Pounder, R E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b WALSGRAVE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ERADICATION THERAPY; FEMALE; GASTRIN BLOOD LEVEL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; STOMACH SUCTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BREATH TESTS; CROSS-OVER STUDIES; FEMALE; GASTRIC ACID; GASTRINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; UREA;

EID: 0346736521     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01488.x     Document Type: Article

References (34)

1. Verdú EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
2. Verdú EF, Armstrong D. Idström J-P. et al. Effect of curing Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 37: 743-8.
3. van Herwaarden MA, Samson M, van Nispen CHM, Mulder PGH, Smout AJPM. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13: 731-40.
4. Martínek J, Blum AL, Stolte M, et al. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 27-34.
5. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
6. Verdú EF, Armstrong D, Idström J-P, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 1551-6.
7. Labenz J, Tillenburg B, Peitz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576-81.
8. Martínek J, Kuzela L, Spicak J, Vavrecka A. Review article: the clinical influence of Helicobacter pylori in effective acid suppression - implications for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 979-90.
9. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
10. Pounder RE, Lanzon-Miller S, Smith JTL, et al. Royal Free Protocol for 24-hour intragastric acidity and plasma gastrin concentration. Dig Dis 1990; 8(Suppl. 1): 10-7.
11. Healey Z, Calam J. Inhibiting acid and Helicobacter pylori? Gut 1997; 41: 125-6.
12. van Herwaarden MA, Samson M, Smout AJPM. 24-h recording of intragastric pH: technical aspects and clinical relevance. Scand J Gastroenterol 1999; 230(Suppl.): 9-16.
13. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
14. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H.K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22 438-46.
15. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of eight days of dosing with rabeprazole versus omeprazole on the 24-hour gastric acidity and plasma gastrin concentrations in healthy young subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
16. Williams MP, Sercombe J, Pounder RE. Correlation between the 5-hour and 24-hour integrated plasma gastrin concentration. Gut 2000; 46(Suppl. 11): A85(Abstract).
17. 13C-UBT for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 1991; 3: 915-21.
18. 13C-urea breath test. Gastroenterology 1996; 110: A144(Abstract).
19. Williams MP, Hamilton MI, Sercombe JC, Pounder RE. Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. Aliment Pharmacol Ther 1997; 11: 705-10.
20. Bryant MG, Adrian TE, Gastrin. In: Bloom SR, Long RG, eds, Radioimmunoassay of Gut Regulatory Peptides. London: Saunders. 1982: 51-9.
21. Bercik P, Verdú EF, Armstrong D. et al. The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 947-55.
22. Pantoflickova D, Bercik P, Blum AL. Omeprazole: Helicobacter pylori makes thee greater yet. Gut 1999; 44: 448-9.
23. Gillen D, Wirz AA, Neithercut WD, Ardill JES, McColl KEL. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
24. Marshall B, Langton S. Urea hydrolysis in patients with Campylobacter pyloridis infection, Lancet 1986; i: 965-6.
25. Labenz J, Tillenburg B, Peitz U, et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997; 41: 33-6.
26. Moore JG, Wolfe M. The relation of plasma gastrin to the circadian rhythm of gastric acid secretion in man. Digestion 1973; 9: 97-105.
27. Pfeiffer A, Krömer W, Friemann J, et al. Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease. Gut 1995; 36: 813-8.
28. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection with patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
29. O'Connor HJ. Review article: Helicobacter pylori and gastrooesophageal reflux disease - clinical implications and management. Aliment Pharmacol Ther 1999; 13: 117-27.
30. Dent J. Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1994; 29(Suppl. 201): 55-61.
31. Katz PO, Anderson C, Khoury R, Castell DO. Gastroesophageal reflux is associated with nocturnal gastric acid breakthrough on proton pump inhibitors BID. Aliment Pharmacol Ther 1998; 12: 1231-4.
32. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.
33. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000; 14: 1049-56.
34. van Herwaarden MA, Samson M, Smout AJPM. Helicobacter pylori eradication increases nocturnal acid breakthrough. Aliment Pharmacol Ther 2000; 14: 961-2.